Clinical trials: Nutritional Risk
Hypercholesterolemia
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Primary Objective: To provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to…
- Trial name
- NCT02476006
- Testing
- ALIROCUMAB SAR236553 (REGN727), ezetimibe, atorvastatin
- Where
- 153 sites in Austria, Belgium and 14 more
- Volunteers
- 998 people
- Sponsor
- Sanofi
Hypercholesterolemia, Cardiovascular Disease
Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia
The hypothesis of this study is that soluble fibre may contribute to a reduction of the low density lipoprotein cholesterol (LDL-c), and the combined effect with a statin may achieve an optimisation of the cholesterol-lowering…
- Trial name
- NCT00502047
- Testing
- Plantago ovata husk
- Where
- Spain
- Volunteers
- 255 people
- Sponsor
- Rottapharm Spain
Obesity, Intra-Abdominal Fat
Effect of a Probiotic on Visceral Fat Accumulation
The study's main objective is to investigate if an extract containing the probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the accumulation of abdominal visceral fat in people with…
- Conditions
- Obesity, Intra-Abdominal Fat, Subcutaneous Fat, Abdominal
- Trial name
- BIFFAT (NCT02921217)
- Testing
- Active Probiotic, Inactivated probiotic, Control
- Where
- Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
- Trial name
- CLEAR Wisdom (NCT02991118)
- Testing
- bempedoic acid
- Where
- 2 sites in United States
- Volunteers
- 779 people
- Sponsor
- Esperion Therapeutics, Inc.
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
This clinical study was designed to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated…
- Conditions
- Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
- Trial name
- ORION-3 (NCT03060577)
- Testing
- Inclisiran, Evolocumab
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Hip Injuries, Fractures, Hip
Mitigation of Major Hip Injury Due to Fall With a Smart Belt
Multi-center, comparative, non-significant risk adaptive study with retrospective controls. After providing informed consent and being screened for eligibility, intervention subjects will be prescribed and provided an…
- Conditions
- Hip Injuries, Fractures, Hip, Fall Injury, Fall Risk
- Trial name
- NCT05245097
- Testing
- Tango Belt, Standard of Care (SOC)
- Where
- 10 sites in United States
- Volunteers
- 471 people
- Sponsor
- ActiveProtective Technologies, Inc
Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with…
- Trial name
- OPTIMA (NCT07034690)
- Testing
- Educational Material, Standard of care
- Where
- United Arab Emirates
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)
The primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback…
- Trial name
- NCT02194608
- Testing
- Home telehealth system
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Undernutrition
Effects of Oral Nutritional Supplementation in Children at Risk of Undernutrition
This prospective, randomized, controlled study will evaluate the effects of oral nutritional supplementation plus dietary counseling versus dietary counseling alone in children at nutritional risk.
- Trial name
- NCT05239208
- Testing
- Oral Nutrition Supplement (ONS) Group, Control Group
- Where
- Vietnam
- Volunteers
- 330 people
- Sponsor
- Abbott Nutrition
Hypercholesteremia
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
- Trial name
- NCT00347217
- Where
- 215 sites in Netherlands
- Volunteers
- 3,840 people
- Sponsor
- AstraZeneca
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Hypercholesterolemia
Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia
This trial is to compare the efficacy, safety and tolerability of Rosuvastatin with Atorvastatin by assessing the change of LDL-C in patients with hypercholesterolemia and history of coronary heart disease (CHD) or risk…
- Trial name
- NCT00683618
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 6 sites in China
- Volunteers
- 934 people
- Sponsor
- AstraZeneca
Postmenopausal Osteoporosis
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis.
- Trial name
- NCT00529373
- Testing
- Odanacatib, Vitamin D3, Calcium carbonate
- Volunteers
- 16,071 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with…
- Trial name
- NCT01042769
- Testing
- Aleglitazar
- Where
- 810 sites in United States, Argentina and 25 more
- Volunteers
- 7,226 people
- Sponsor
- Hoffmann-La Roche
Low Muscle Strength, Malnutrition
Efficacy of Oral Nutritional Supplement in Community-Dwelling Adults Following Acute Care
The study aims to determine the effects of Oral Nutritional Supplement (ONS) added to usual care on body weight compared with usual care alone in community-dwelling adults aged 55 years and older who are at risk of malnutrition…
- Trial name
- NCT07753239
- Testing
- ONS, Standard of Care (SOC)
- Where
- 7 sites in Thailand
- Volunteers
- 304 people
- Sponsor
- Abbott Nutrition
Dyslipidemia
Dyslipidemia in Cardiovascular Disease
A multi-center, randomized, double-blinded equivalence clinical trial to evaluate efficacy and safety of LipiLou 20 mg versus Lipitor 20 mg in hypercholesterolemic patients with higher risk cardiovascular disease in Korea.
- Trial name
- KoLipilou (NCT01029522)
- Testing
- Atorvastatin (Lipilou), Atorvastatin (Lipitor)
- Volunteers
- 244 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Obesity
Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives
This observational non-interventional study will assess (under conditions of clinical practice in daily routine) the antihypertensive efficacy of telmisartan treatment with or without active promotion of lifestyle changes in…
- Trial name
- NCT00539487
- Where
- 2,389 sites in Germany
- Volunteers
- 5,827 people
- Sponsor
- Boehringer Ingelheim